Twitter Beğeni Hilesi

Don’t miss Dave Hallett, interim CEO & CSO, at the #NovAliXConference next week, discussing how Exscientia is disrupting the drug discovery status quo - integrating generative AI drug design with robotic automation of chemistry synthesis & testing to design higher quality drugs.

Congratultions John P. Overington on becoming our new CTO Exscientia. We all look fwd to further accelerating our AI-led #drugdesign & fully realising the transformative potential of integrating AI-design with automated experimentation! shorturl.at/gR5PI

Wellcome to Exscientia Marie-Louise Fjällskog! We look forward to leveraging your incredible #oncology expertise in building out our AI-designed #pipeline and #clinicaldevelopment strategy. So many patients waiting - so much to do! shorturl.at/gR5PI

Don't miss Richard J Law 🚜--🇺🇦 🍉 at Barclays Digital and Disruptive Technology Conference today

Today our #CFO and Chief Strategy Officer, Ben Taylor, will be having a discussion about all things Exscientia at the 45th Goldman Sachs Healthcare conference. Tune in at 3:20p.m. EDT - a webcast link is available at event.webcasts.com/starthere.jsp?… $EXAI #drugdiscovery #AI #automation

Don’t miss John P. Overington, our new CTO, presenting at #DIA2024 next week. He'll provide a contextual perspective of the transition of structured relational data to unstructured exploration of latent space using #LLMs

Listen to the The Next Big Thing podcast with our CFO Ben Taylor, Mobeen Tahir and Chris Ganetti, discussing how generative AI can revolutionise the search for novel drugs and our pioneering approach to AI in drug discovery. #ai #drugdiscovery

Proud to be awarded the #PrixGalien International 2024 for Best Digital Health Solution. Our #precisionmedicine platform previously won the UK and US national awards. Thank you Prix Galien & our fab team Exscientia

Register now for the CCDC Cambridge webinar tomorrow! Chris Radoux will detail how Exscientia is  automating structure-based design for kinase hit identification. Register here: register.gotowebinar.com/register/24053… #AI #Automation

Interim CEO Dave Hallett will share our ‘Human-led AI drug discovery’ approach at tomorrow’s Milner Symposium Cambridge University. Integrating human science, AI-design & process automation, we aim to cut down discovery time for improved drug design. milner.cam.ac.uk/milner-therape… #AI

Thank you Tanuja Randery Amazon Web Services for hosting our interim CEO Dave Hallett on the Conversations with Leaders podcast. Hear Dave’s views on using technology to speed up the design and discovery of novel drug candidates, and his vision for Exscientia. aws.amazon.com/podcasts/cwl-h… $EXAI

Announcing our state-of-the-art GenAI platform to advance drug discovery, built using Amazon Web Services tech, integrating generative AI drug design & robotic lab #automation to further accelerate delivery of high-quality drugs at faster speed & lower cost: shorturl.at/dmSFG $EXAI

We’re thrilled to be working with READDI, gathering their preclinical drug testing expertise to evaluate and improve a range of AI-designed antiviral compounds for pandemic preparedness. linkedin.com/feed/update/ur… #AI #PandemicPreparedness

We’re backing our #GenAI design capabilities, by acquiring the full rights to our lead pipeline asset, our oral CDK7 inhibitor ‘617. Read more here: investors.exscientia.ai/press-releases… $EXAI

Today we entered a definitive agreement to combine with Recursion (Nasdaq: RXRX), a complementary combination that aligned with our missions to industrialise drug discovery to deliver better treatments to patients faster and at lower cost. shorturl.at/e7iqa

Watch Chris Gibson & Dave Hallett talk about the plan to bring together the people, partnerships, pipelines & research platforms of Exscientia and Recursion to truly accelerate the discovery of better drugs for patients. #AI #drugdiscovery

We’re thrilled Nicola Richmond Ph.D., will be joining our team in Sept as Chief Scientist, AI. She brings over 20 years of experience operating at the intersection of drug discovery and technology. She will be leading our work to develop AI solutions for drug discovery. #AI

Read our #EUROTOX2024 poster to learn about our drug-induced liver injury models, developed with more DILI-relevant features and endpoints, for improved early estimation of DILI in potential drug candidates and to improve drug safety and attrition bit.ly/EuroTox_EXAI

Read our RSC BMCS #NTGH24 poster to learn more about how we’re using novel AI-designed bispecifics to tackle malaria - hitting two targets simultaneously to potentially prevent resistance emerging. bit.ly/EXSmalaria #AI #DrugDiscovery #Malaria

September is #BloodCancerAwarenessMonth – a time to highlight the urgent need to deliver new treatments to blood cancer patients. We’re harnessing our AI –driven platform to tackle some of the hardest-to-treat blood cancers by targeting the underlying disease drivers. #AI